ÁñÁ«¹ÙÍø

The Faridani lab uses state-of-the-art technology in the field of "single cell omics" to tackle hard-to-crack problems of cancer treatment, with a focus on pancreatic cancer and other solid tumours. The main goal of the lab is to tailor treatment for each patient.

The CTRU studies the building blocks of cell architecture and develops therapeutic strategies based on drug-targeting these building blocks. Our focus is the actin cytoskeleton that is responsible for the internal scaffolds of cells, the generation and reaction to force exerted by the environment and the movement of cells throughout the body.Ìý

Our laboratory utilises a variety of in vitro, ex vivo and in vivo techniques to dissect out the role of key transporters and metabolic enzymes in cancer growth. We have determined a number of metabolic pathways that are differentially regulated in breast cancer, prostate cancer, melanoma and more recently glioblastoma.

The Khachigian Group has 2 principal aims:

1. To better understand how potentially harmful genes are controlled in vascular cells.Ìý
2. To develop novel vascular therapeutic agents for cardiovascular and inflammatory disease, tumour growth and metastasis.Ìý

The critical role of the tumour microenvironment in cancer growth and survival suggests it is vulnerable to intervention.ÌýWe aim to improve the survival rate of cancer patients by deciphering and therapeutically exploiting elements of the tumour microenvironment that facilitate chemoresistance.

Ìý

The Cancer Systems Microscopy Lab aims to contribute to improved cancer treatment outcomes by advancing: Precision Diagnostics;ÌýTargeted Therapies; and Fundamental Insights.

Our research group is at the intersection of systems immunology and artificial intelligence (AI). Our vision is to develop cutting-edge knowledge and tools to unravel the intricate workings of T cells and harness their potential in modern immunotherapy.

Our team is dedicated to improving treatments for patients with pancreatic cancer. We have developed a patient-centered drug development pipeline focusing on the unmet clinical challenges faced by patients which include, the heterogeneity of tumours, the scar tissue fortress, and tumour metastasis.

We are a molecular and cell biology laboratory with a research focus in blood development and leukemia. Our research interest lies in identifying critical components of the hematopoietic transcriptional network in healthy and leukemic blood stem cells and how these govern stemness.Ìý

Despite an overall improvement in survival in children with cancer, survival rates for those with aggressive cancers, such as high-risk neuroblastoma and brain tumours, remain dismal. Moreover, survivors frequently have life-long health issues due to the toxic effects of chemotherapy. Targeted and less toxic therapies are urgently required.

Our lab studies the molecular and metabolic mechanisms that underlie biological ageing, with a focus on its impacts on female fertility. A key mechanistic interest for the lab is the role of altered metabolism, including the molecular metabolism of the redox cofactor nicotinamide adenine dinucleotide (NAD+).

The Centre for Molecular Oncology applies basic, translational and clinical approaches to understanding cancer biology through patient-centred discovery programs, and uses this information to improve patient outcomes through clinical trials.Ìý